Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt (Single Center Study)

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

Inclusion Criteria:

• mild- moderate COVID-19 confirmed by PCR

Exclusion Criteria:

1. Patients on renal dialysis
2. Severe COVID-19 cases
3. Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia).
4. Children < 12 years
5. Pregnant and breast feeding women
6. Exacerbation of hepatitis B